InvestorsHub Logo
Followers 2
Posts 220
Boards Moderated 0
Alias Born 10/03/2019

Re: None

Tuesday, 07/28/2020 9:17:38 AM

Tuesday, July 28, 2020 9:17:38 AM

Post# of 9432
PHASE1-Dosing Complete WELL TOLERATED!

NEW YORK, July 28, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC. The dosing of 18-MC was well tolerated in humans and will help advance planning for a Phase 2a clinical trial in opioid addiction. Further, the study has not incurred any delays due to the COVID-19 pandemic and the Multiple Ascending Dose (MAD) study is on track according to the original development timeline.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNMD News